Optical Imaging for Uveal Melanoma patients

Optical Imaging for the follow-up of Uveal Melanoma patients - Optical Imaging for Uveal Melanoma patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON57016

Enrollment

Registered

2024-04-22

Start date

2025-04-29

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uveal Melanoma

Interventions

Not applicable.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Diagnosis of primary uveal melanoma - No history of previous uveal melanoma treatments - No diagnosis of other retinal diseases - Uveal melanoma patients who will be treated with either brachytherapy or proton beam therapy

Exclusion criteria

Exclusion criteria: - Subjects who are not legally capable - Subjects under the age of 18

Design outcomes

Primary

Measure	Time frame
Main study parameters/endpoints: For Ru-106 brachytherapy and PBT treated patients between each timepoint: Primary objective: • Location of FAF changes • Characteristic FAF changes (mottling pattern and rim of increased FAF).	—

Secondary

Measure	Time frame
Secondary objectives: • For brachytherapy, the diameter of the FAF changes compared to the dimensions of the used applicator. • For PBT, distances of retina with FAF changes to the clip locations. • Relation of FAF changes to abnormalities seen on OCT and funduscopic imaging both at the same timepoint and at later timepoints.	—

Countries

Netherlands

Contacts

Public ContactI. E. Mulder

Leids Universitair Medisch Centrum

i.e.mulder@lumc.nl071-5296217

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)